Skip to search formSkip to main contentSkip to account menu

GMI-1070

Known as: Pan-Selectin Antagonist GMI-1070 
A synthetic, glycomimetic molecule and pan-selectin antagonist, with potential use in a vaso-occlusive crisis. Upon administration, GMI-1070 prevents… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Introduction: The pan-selectin antagonist rivipansel (GMI-1070) reduced intravascular arrest of red/white blood cell aggregates… 
2012
2012
Abstract 87 Introduction: Engagement of selectins by their ligands leads to cellular activation and adhesion and plays a role in… 
2011
2011
Abstract 851 Introduction: E-selectin expression by endothelium plays dual roles in inflammation by supporting slow rolling and… 
2011
2011
Abstract 3273 Introduction: E- and P-selectin have structural similarities and both facilitate white blood cell tethering on… 
2010
2010
Abstract 1632 GMI-1070 is a pan-selectin inhibitor that targets E-, P-, and L-selectins and has shown activity in multiple animal… 
2010
2010
Abstract 262 Adhesion molecules are critically involved in the pathophysiology of sickle cell disease (SCD). A growing body of… 
2010
2010
Methods Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes in Sickle Cell Patients not in Crisis SI… 
Review
2009
Review
2009
Abstract 1526 Poster Board I-549 Introduction GMI-1070 is a pan-selectin inhibitor which targets E-, P-, and L-selectin, and has… 
2008
2008
Acute vaso-occlusion (VOC) in patients with sickle cell disease (SCD) induces intense pain arising from organ damage and is the… 
2007
2007
Rational design of glycomimetic inhibitors based on the bioactive conformation of functional carbohydrates provides new…